缓解期炎性肠病伴肠易激综合征样症状机制的研究进展

doi:10.3969/j.issn.1007-9572.2016.28.025

摘要/Abstract

摘要： 炎性肠病（IBD）是一种病因不十分清楚的慢性非特异性肠道炎性疾病，缓解期IBD（IBDR）患者常伴有肠易激综合征（IBS）样症状。IBS样症状的存在导致患者的生活质量降低，影响医生对病情的评估及治疗策略的选择。因此，本文对IBDR患者伴有IBS样症状的机制进行综述，得出IBDR伴IBS样症状与肠道低度炎症和神经重塑均有关联，也可能为IBD合并了IBS。

关键词: 炎性肠疾病, 肠易激综合征, 炎症, 神经重塑

Abstract: Inflammatory bowel disease（IBD） is a chronic nonspecific inflammatory bowel disease with not very clear causes,IBD during remission（IBDR） patients often have irritable bowel syndrome（IBS）-like symptoms.The presence of IBS-like symptoms leads to reduced quality of life of patients,and influences assessment of disease and choice of treatment strategies of doctors.Therefore,the paper reviews the mechanism of IBDR patients with IBS-like symptoms,and concludes that IBDR with IBS-like symptoms was related to intestinal low-grade inflammation and nerve remodeling,and may also have combined IBS for IBD.

Key words: Inflammatory bowel diseases, Irritable bowel syndrome, Inflammation, Nerve remodeling

曹明为, 刘玉兰, 马静静, 董卫国. 缓解期炎性肠病伴肠易激综合征样症状机制的研究进展[J]. 中国全科医学, 2016, 19(28): 3506-3509.

CAO Ming-wei, LIU Yu-lan, MA Jing-jing, DONG Wei-guo.. Research Progress of Mechanism of Inflammatory Bowel Disease Patients with Irritable Bowel Syndrome-like Symptoms during Remission[J]. Chinese General Practice, 2016, 19(28): 3506-3509.

参考文献

［1］MINDERHOUD I M,OLDENBURG B,WISMEIJER J A,et al.IBS-like symptoms in patients with inflammatory bowel disease in remission:relationships with quality of life and coping behavior［J］.Dig Dis Sci,2004,49（3）:469-474. ［2］KEOHANE J,O’MAHONY C,O’MAHONY L,et al.Irritable bowel syndrome-type symptoms in patients with inflammatory bowel disease:a real association or reflection of occult inflammation?［J］.Am J Gastroenterol,2010,105（8）:1788-1795. ［3］VIVINUS-NEBOT M,FRIN-MATHY G,BZIOUECHE H,et al.Functional bowel symptoms in quiescent inflammatory bowel diseases:role of epithelial barrier disruption and low-grade inflammation［J］.Gut,2014,63（5）:744-752. ［4］ZIMMERMAN L A,SRINATH A I,GOYAL A,et al.The overlap of functional abdominal pain in pediatric Crohn’s disease［J］.Inflamm Bowel Dis,2013,19（4）:826-831. ［5］KANG S,DENMAN S E,MORRISON M,et al.Dysbiosis of fecal microbiota in Crohn’s disease patients as revealed by a custom phylogenetic microarray［J］.Inflamm Bowel Dis,2010,16（12）:2034-2042. ［6］MACHIELS K,JOOSSENS M,SABINO J,et al.A decrease of the butyrate-producing species Roseburia hominis and Faecalibacterium prausnitzii defines dysbiosis in patients with ulcerative colitis［J］.Gut,2014,63（8）:1275-1283. ［7］LOPEZ-SILES M,MARTINEZ-MEDINA M,ABELLA C,et al.Mucosa-associated faecalibacterium prausnitzii phylotype richness is reduced in patients with inflammatory bowel disease［J］.Appl Environ Microbiol,2015,81（21）:7582-7592. ［8］SOKOL H,PIGNEUR B,WATTERLOT L,et al.Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients［J］.Proc Natl Acad Sci U S A,2008,105（43）:16731-16736. ［9］QUEVRAIN E,MAUBERT M A,MICHON C,et al.Identification of an anti-inflammatory protein from Faecalibacterium prausnitzii,a commensal bacterium deficient in Crohn’s disease［J］.Gut,2016,65（3）:415-425. ［10］BROZ P.Getting rid of the bad apple:inflammasome-induced extrusion of Salmonella-infected enterocytes［J］.Cell Host Microbe,2014,16（2）:153-155. ［11］BURET A G,BHARGAVA A.Modulatory mechanisms of enterocyte apoptosis by viral,bacterial and parasitic pathogens［J］.Crit Rev Microbiol,2014,40（1）:1-17. ［12］CARBONERO F,BENEFIEL A C,GASKINS H R.Contributions of the microbial hydrogen economy to colonic homeostasis［J］.Nat Rev Gastroenterol Hepatol,2012,9（9）:504-518. ［13］BIASI F,LEONARDUZZI G,OTEIZA P I,et al.Inflammatory bowel disease:mechanisms,redox considerations,and therapeutic targets［J］.Antioxid Redox Signal,2013,19（14）:1711-1747. ［14］SMITH F,CLARK J E,OVERMAN B L,et al.Early weaning stress impairs development of mucosal barrier function in the porcine intestine［J］.Am J Physiol Gastrointest Liver Physiol,2010,298（3）:352-363. ［15］FARHADI A,KESHAVARZIAN A,KAR L D,et al.Heightened responses to stressors in patients with inflammatory bowel disease［J］.Am J Gastroenterol,2005,100（8）:1796-1804. ［16］VANUYTSEL T,VAN WANROOY S,VANHEEL H,et al.Psychological stress and corticotropin-releasing hormone increase intestinal permeability in humans by a mast cell-dependent mechanism［J］.Gut,2014,63（8）:1293-1299. ［17］OVERMAN E L,RIVIER J E,MOESER A J.CRF induces intestinal epithelial barrier injury via the release of mast cell proteases and TNF-α［J］.PLoS One,2012,7（6）:e39935.DOI:10.1371/journal.pone.0039935. ［18］MORRISON G,VAN LANGENBERG D R,GIBSON S J,et al.Chronic pain in inflammatory bowel disease:characteristics and associations of a hospital-based cohort［J］.Inflamm Bowel Dis,2013,19（6）:1210-1217. ［19］ALCALDE-CABERO E,ALMAZAM-ISLA J,GARCIA-MEINO A,et al.Incidence of multiple sclerosis among European Economic Area populations,1985—2009:the framework for monitoring［J］.BMC Neurol,2013,13:58. ［20］LEE D,ALBENBERG L,COMPHER C,et al.Diet in the pathogenesis and treatment of inflammatory bowel diseases［J］.Gastroenterology,2015,148（6）:1087-1106. ［21］KAJIURA T,TAKEDA T,SAKATA S,et al.Change of intestinal microbiota with elemental diet and its impact on therapeutic effects in a murine model of chronic colitis［J］.Dig Dis Sci,2009,54（9）:1892-1900. ［22］DEVKOTA S,WANG Y,MUSCH M W,et al.Dietary-fat-induced taurocholic acid promotes pathobiont expansion and colitis in Il10-/-mice［J］.Nature,2012,487（7405）:104-108. ［23］ZHAO H,ZHANG H,WU H,et al.Protective role of 1,25（OH）2 vitamin D3 in the mucosal injury and epithelial barrier disruption in DSS-induced acute colitis in mice［J］.BMC Gastroenterol,2012,12:57. ［24］SCHEPENS M A,SCHONEWILLE A J,VINK C,et al.Supplemental calcium attenuates the colitis-related increase in diarrhea,intestinal permeability,and extracellular matrix breakdown in HLA-B27 transgenic rats［J］.J Nutr,2009,139（8）:1525-1533. ［25］FEAGAN B G,SANDBORN W J,MITTMANN U,et al.Omega-3 free fatty acids for the maintenance of remission in Crohn disease:the EPIC Randomized Controlled Trials［J］.JAMA,2008,299（14）:1690-1697. [26] MARSH A, ESLICK E M, ESLICK G D. Does a diet low in FODMAPs reduce symptoms associated with functional gastrointestinal disorders? A comprehensive systematic review and meta-analysis [J]. Eur J Nutr,2015,55 (3):897-906. [27] MARSHALL J K, THABANE M, BORGANKAR M R, et al. Postinfectious irritable bowel syndrome after a food-borne outbreak of acute gastroenteritis attributed to a viral pathogen [J]. Clin Gastroenterol Hepatol,2007,5 (4):457-460. [28] BRIERLEY S M,LINDEN D R. Neuroplasticity and dysfunction after gastrointestinal inflammation [J]. Nat Rev Gastroenterol Hepatol,2014,11 (10):611-627. [29] AKBAR A, YIANGOU Y, FACER P, et al. Expression of the TRPV1 receptor differs in quiescent inflammatory bowel disease with or without abdominal pain [J]. Gut,2010,59 (6):767-774. [30] MINDE RHOUD I M,OLDENBURG B,SCHIPPER M E, et al. Serotonin synthesis and uptake in symptomatic patients with Crohn's disease in remission [J]. Clin Gastroenterol Hepatol,2007,5 (6):714-720. [31] SCHMID J,LANGHORST J,GAB F,et al. Placebo analgesia in patients with functional and organic abdominal pain: a f MRI study in IBS,UC and healthy volunteers [J]. Gut,2015,64 (3):418-427. [32] 杨华丽，吴小平。炎症性肠病与肠易激综合症的相关性研究进展 [J]. 国际消化病杂志，2014,34 (5):299-306. [33] JONEF JALL B,STRID H,OHMAN L,et al. Characterization of IBS-like symptoms in patients with ulcerative colitis in clinical remission [J]. Neurogastroenterol Motil,2013,25 (9):756. [34] SPRAKES M B, HAMLIN P J, FORD A C. Utility of fecal calprotectin in differentiating active inflammatory bowel disease from coexistent irritable bowel syndrome [J]. Am J Gastroenterol,2011,106 (1):166.

[1]	王立娜, 雷警输, 李奎宝, 王睿颖, 李新苗, 王芳芳, 郭晓荣, 牛瑞浩, 赵伟, 周芳芳, 赵京晶, 李忠佑. 急性心肌梗死患者炎症反应研究进展[J]. 中国全科医学, 2026, 29(06): 790-801.
[2]	陈荟雨, 徐紫燕, 李玉红. 孕晚期女性膳食炎症指数和泌乳启动延迟的相关性研究[J]. 中国全科医学, 2025, 28(35): 4442-4448.
[3]	倪明珠, 王莉, 许珍晶, 石桥, 侯志峰. Wilson病合并轻度认知障碍患者血清晚期糖基化终产物受体/核因子κB通路关键分子表达水平变化及其与认知功能关系的研究[J]. 中国全科医学, 2025, 28(35): 4430-4434.
[4]	王碧优, 高鹰, 尤俊方, 刘莉, 张卿, 苏海燕. 心血管疾病风险人群脂质比值与炎症指标的典型相关性研究[J]. 中国全科医学, 2025, 28(33): 4132-4139.
[5]	董称仙, 邵健将, 姚腾, 翟金婵, 马娇龙, 胡云华, 刘文, 牛强, 李小菊, 闫贻忠. 孕妇不同膳食模式下膳食炎症指数与妊娠期贫血的关联研究[J]. 中国全科医学, 2025, 28(29): 3674-3683.
[6]	卢冬磊, 杨风英, 冯展鹏, 曹立全, 谭思洁. 同期训练可改善伴有超重或肥胖2型糖尿病患者的健康效应：一项Meta分析[J]. 中国全科医学, 2025, 28(27): 3410-3421.
[7]	赵玉晴, 王伟, 陈立沅, 油惠娟, 魏莹, 王清路, 杨风英. 肝脏巨噬细胞极化：运动防治非酒精性脂肪性肝病的新靶向[J]. 中国全科医学, 2025, 28(27): 3456-3465.
[8]	刘容, 李国信, 李昀泽, 梁丽喆, 陆飞, 党世竟, 吴红江, 刘晓颐. 多种炎症和氧化应激综合指标与下肢动脉硬化闭塞症的相关性和诊断价值研究[J]. 中国全科医学, 2025, 28(18): 2234-2240.
[9]	韩超, 占小飞, 严沁, 俞鑫, 童燕, 庞珍珍, 解鸿翔. 全身炎症综合指数在亚急性甲状腺炎辅助诊断中的临床应用价值研究[J]. 中国全科医学, 2025, 28(18): 2241-2246.
[10]	刘青芳, 韦有仕, 肖斐, 周春香, 刘群, 袁慧, 曹天然. 麦角硫因激活核因子E2相关因子2/血红素加氧酶1信号通路改善血管性痴呆大鼠认知功能障碍研究[J]. 中国全科医学, 2025, 28(17): 2156-2162.
[11]	陈伊静, 许琪, 刘忠典, 覃玲巧, 陈淑萍, 唐薇婷, 钟秋安. 己糖胺生物合成通路在血管内皮炎症中的调控作用研究[J]. 中国全科医学, 2025, 28(15): 1871-1877.
[12]	徐军, 高亚南, 徐涯鑫, 姚亭, 陈亚梅. 炎症性肠病患者疾病负担的潜在剖面分析及其影响因素研究[J]. 中国全科医学, 2025, 28(14): 1744-1750.
[13]	李伊婷, 徒文静, 尹婷婷, 梅紫琦, 张苏闽, 王萌, 徐桂华. 人工智能在炎症性肠病患者营养管理中应用的范围综述[J]. 中国全科医学, 2025, 28(14): 1709-1716.
[14]	李冰, 奚志, 王洋, 修佳琦, 郭前成, 于晨晨, 孙斯雨, 杨霄鹏. 血压变异性和系统性免疫炎症指数与脑小血管病患者发生颅内动脉负性重塑的相关性研究[J]. 中国全科医学, 2025, 28(14): 1751-1757.
[15]	谭会会, 毛伟, 杨子涵. 膜联蛋白A1在呼吸系统疾病中的研究进展[J]. 中国全科医学, 2025, 28(13): 1668-1673.